Novartis

By Dave Muoio May 21, 2019
Cala Health, a wearable neuromodulation therapy startup focused on chronic diseases, has closed a $50 million Series C financing round. Novartis, Baird Capital, LifeSci Venture Partners, TriVentures and other unnamed backers participated, as did returning investors JJDC, Lux Capital, Lightstone Ventures, Action Potential Venture Capital, dRx Capital and GV. WHAT THEY DO Stanford University...
By Dave Muoio May 21, 2019
This morning Verily announced a series of new strategic partnerships with four global pharmaceutical companies that will bring low-burden digital data collection and analysis tools to clinical research projects. Alongside Novartis, Otsuka, Pfizer and Sanofi, the Alphabet subsidiary will employ its Project Baseline platform to increase the number and diversity of study populations by making it...

Credit: Pilloxa

By Leontina Postelnicu May 9, 2019
Transplant clinics in Sweden will see digital health startup Pilloxa’s innovation be deployed in a new collaboration with Novartis division Sandoz Nordics to improve medication adherence, announced today.   Founded in 2015, Pilloxa has developed a platform that consists of an intelligent pillbox, an app and a cloud solution, along with data driven services, that aims to help patients take their...
Novartis
By Leontina Postelnicu March 4, 2019
Pharma giant Novartis and O2 innovation arm Wayra UK revealed last week that Virtue, TestCard and ExSeed would join its nine-month Health Hub accelerator programme. “After a rigorous judging day, I believe the innovations these three startups offer will make a significant difference to patients and the NHS,” said Novartis Market Access Director Fiona Bride. “I look forward to supporting them over...
By MobiHealthNews December 26, 2018
The pharma industry has become increasingly interested in the digital health space over the last few years, but this quarter numerous projects that have been in the works for years have finally came to fruition. For instance, Pear's reSET, the first digital therapeutic cleared by the FDA, was recently launched to commercial markets.  But that wasn’t the only advance in the space as pharma...
By Laura Lovett December 10, 2018
The FDA has officially cleared reSET-O — a digital therapeutic to treat opioid use disorder (OUD) jointly developed by Pear Therapeutics and Sandoz, a division of Novartis — a little over a year after it was granted an Expedited Access Pathway designation from the agency.  This announcement makes reSET-O the first digital therapeutic to treat patients with OUD. Patients will need a valid...

Novartis' recently-opened digital health innovation lab in San Francisco. Photo courtesy Novartis on Twitter.

By Jonah Comstock November 21, 2018
Last month, Novartis announced that it would be cutting 2,200 jobs as part of a restructuring of the company focusing on particular priorities. “The overall strategy we have is to focus the company as a leading medicines company powered by digital technologies,” CEO Vas Narasimhan told STAT News last month. “What that has meant is to exit certain health care sectors or segments … — so we exited...
By Dave Muoio November 20, 2018
reSET — a substance use disorder treatment that was the first software-only therapeutic cleared by the FDA — is now commercially available for clinicians to prescribe to their patients, according to a release from Pear Therapeutics and Sandoz, a division of Novartis with which Pear partnered back in April. But while physical prescription drugs are usually handled through a pharmacy, the process...
NovioSense's artist conception of its device in use.

NovioSense's artist conception of its device in use.

By Jonah Comstock November 20, 2018
Last week, Alphabet subsidiary Verily Life Sciences announced the end, at least for the foreseeable future, of its glucose-sensing contact lens collaboration with Novartis. Verily CTO Brian Otis gave his thoughts in a blog post at the time, stressing the learnings the company got from the project. In a recent interview with MobiHealthNews, Novartis Global Head of Digital Development Jacob LaPorte...
By Jonah Comstock November 16, 2018
Four years after announcing an ambitious — and often ridiculed — project to create a glucose-sensing contact lens along with Novartis subsidiary Alcon, Alphabet's Verily is throwing in the towel, the company announced in a blog post today. It will continue to work on two other medical contact lens projects, aimed at presbyopia and cataract surgery recovery. "Our clinical work on the glucose-...